ASH 2022 | TELLOMAK: lacutamab alone or with chemotherapy in patients with mycosis fungoides or Sézary syndrome
Neha Mehta-Shah, MD, Washington University in St Louis, St Louis, MO, discusses updated results from the Phase II TELLOMAK study (NCT03902184), looking at lacutamab alone or combined with chemotherapy for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Genetech/Roch: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Daiichi Sankyo: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Corvus Pharmaceuticals: Research Funding; Celgene: Research Funding; Bristol Myers-Squibb: Research Funding; AstraZeneca: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Karyopharm Therapeutics: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Kyowa Hakko Kirin Co., Ltd.: Membership on an entity’s Board of Directors or advisory committees; Secura Bio: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Verastem: Research Funding.
